camptothecin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (38.33) | 24.3611 |
| 2020's | 37 (61.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZS; Li, D; Qiu, Y; Wu, L; Xu, J; Xu, S; Yang, DH; Yao, H; Zhou, M | 1 |
| Bardia, A; Brufsky, A; Carey, LA; Cortes, J; Cowden, J; Hurvitz, SA; Loibl, S; Piccart, M; Rugo, HS; Spears, P | 1 |
| Bardia, A; Medford, A; Moy, B; Spring, LM | 1 |
| Andress, M; Diamond, JR; Schreiber, AR | 1 |
| Baek, G; Duong, A; Gralow, J; Jung, L | 1 |
| Bardia, A | 2 |
| Ozaki, Y; Takano, T | 1 |
| Da Silva, A; Kabirian, R | 1 |
| Aslam, HM; Khawar, Z; Muzaffar, M; Veeraballi, S | 1 |
| Abe, M; Ishikawa, H; Koyama, K; Murakami, M; Nakamaru, K; Qiu, Y; Shiose, Y; Ueno, S | 1 |
| Bardia, A; Brufsky, A; Cortés, J; Hamilton, E; Henry, S; Hurvitz, SA; Kalinsky, K; Leon-Ferre, R; Loirat, D; Mayer, I; O'Shaughnessy, J; Phan, S; Punie, K; Rugo, HS; Sardesai, S; Tolaney, SM; Traina, T; Zhu, Y | 1 |
| Enzmann, H; Michaleas, S; Moreno Oliver, A; Mueller-Berghaus, J; Müller-Egert, S; Pignatti, F; Sarac, SB; van der Elst, ME; Zander, H | 1 |
| Kwapisz, D | 1 |
| Johmura, Y; Miyoshi, Y; Nakanishi, M; Ohta, T; Taira Nihira, N; Togashi, Y; Wu, W; Zhu, D; Zhu, J | 1 |
| Bravaccini, S; Cortesi, M; Maltoni, R; Pirini, F; Ravaioli, S; Tumedei, MM; Zanoni, M | 1 |
| Furlanetto, J; Loibl, S; Marmé, F | 1 |
| Chen, J; Cong, XJ; Li, W; Luo, T; Ma, F; Pan, Y; Sun, T; Tong, Z; Wang, S; Wang, T; Wang, X; Wu, X; Xu, B; Yang, J; Yao, H; Zeng, X; Zhao, W | 1 |
| Khatun, S; Pebam, M; Putta, CL; Rengan, AK | 1 |
| Chai, Q; Lang, Y; Liao, Y; Liu, X; Tao, W; Wu, B | 1 |
| Cai, Z; Han, TY; He, W; Huan, ML; Zhang, BL; Zhang, YW; Zhao, TT; Zhou, SY | 1 |
| Grinda, T; Pistilli, B; Rassy, E | 1 |
| Chen, QC; Cheng, SX; Dai, Y; Han, YH; Lin, GH; Wang, BC; Zhao, YX | 1 |
| Sidaway, P | 1 |
| Diamond, J; Glode, A; Messersmith, WA; Weiss, J | 1 |
| Fenn, KM; Kalinsky, K | 1 |
| Syed, YY | 1 |
| Dees, S; Ganesan, R; Grewal, IS; Singh, S | 1 |
| Berger, MJ; Harvey, RD; Patron, AM; Seligson, JM; Seligson, ND | 1 |
| Kalinsky, K; McGuinness, JE | 1 |
| Amiri-Kordestani, L; Barnett-Ringgold, K; Beaver, JA; Charlab, R; Cheng, J; Dinin, J; Dorff, SE; Fashoyin-Aje, L; Fiero, MH; Goldberg, KB; Hamed, SS; Osgood, CL; Pazdur, R; Ricks, TK; Song, P; Tang, S; Theoret, MR; Wahby, S; Zhang, L | 1 |
| Dalenc, F; Franchet, C; Nicolaï, V; Sarradin, V; Ung, M | 1 |
| Bousoik, E; Elghazaly, H; Elmazar, MMA; Tolaney, SM; Tolba, MF | 1 |
| Aftimos, P; Bardia, A; Brufsky, A; Carey, LA; Cortés, J; Dalenc, F; Diab, S; Diéras, V; Ferrario, C; Gianni, L; Goldenberg, DM; Hong, Q; Hurvitz, SA; Itri, LM; Kalinsky, K; Loibl, S; Loirat, D; Lynce, F; O'Shaughnessy, J; Oliveira, M; Olivo, MS; Piccart, MJ; Punie, K; Rugo, HS; Sardesai, SD; Schmid, P; Tolaney, SM; Traina, T; Weaver, R; Zelnak, AB | 1 |
| Aftimos, P; Bardia, A; Carey, LA; Cortes, J; Dalenc, F; Diéras, V; Gil, EC; Goldenberg, DM; Hamilton, E; Hong, Q; Hurvitz, SA; Itri, LM; Kalinsky, K; Loirat, D; O'Shaughnessy, J; Oliveira, M; Olivo, M; Punie, K; Recalde, S; Rugo, HS; Sardesai, S; Sharma, P; Tolaney, SM; Traina, T; Tsai, M; Vahdat, L; Zelnak, A | 1 |
| Bardia, A; Blouin, G; Hutchinson, J; Moy, B; Nakajima, E; Rugo, H; Spring, LM; Viscosi, E; Weekes, C | 1 |
| Adams, E; Neven, P; Punie, K; Wildiers, H | 1 |
| Burki, TK | 1 |
| Hosoda, Y; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Hu, T; Li, Q; Liu, C; Ma, Y; Wu, G; Xiong, J; Zhao, Y | 1 |
| Bao, G; Chen, M; Dai, Z; Gao, C; Gong, Z; Krueger, CJ; Liang, X; Zhang, N; Zhou, Y | 1 |
| Adams, S; Esteva, FJ; Tray, N | 1 |
| Cai, K; Chen, Q; Chen, X; Cheng, J; Guo, Q; He, X; Jiang, C; Li, C; Liu, L; Lu, Y; Ruan, C; Sun, T; Zhang, Y | 1 |
| Bardia, A; Nagayama, A; Spring, LM; Zangardi, ML | 1 |
| Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Iannone, R; Isakoff, SJ; Kalinsky, K; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Rugo, HS; Santin, AD; Shah, NC; Sharkey, RM; Sweidan, AM; Tolaney, SM; Vahdat, LT; Washkowitz, S; Wegener, WA | 1 |
| Stirrups, R | 1 |
| Masuda, J; Ozaki, Y; Takano, T | 1 |
| Bardia, A; Kalinsky, K; Mayer, IA | 1 |
| Abramson, V; Anders, C; Berg, J; Carey, LA; Carpenter, JT; Deal, AM; Karginova, O; Kelly Marcom, P; Lin, NU; Liu, MC; Melhem-Bertrandt, A; Melisko, M; Nanda, R; Parker, J; Perou, CM; Peterman, A; Prat, A; Puhalla, S; Smith, JK; Stearns, V; Storniolo, AM; Van Poznak, C; Winer, EP; Wolff, AC | 1 |
| Eichelser, C; Milde-Langosch, K; Müller, V; Pantel, K; Schwarzenbach, H; Stückrath, I; Wikman, H | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Boerner, JL; Boerner, SA; Burger, A; Heilbrun, L; LoRusso, PM; Mueller, KL; Nechiporchik, N; Polin, L; Stark, K; Zoratti, GL | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Rossi, EA; Sharkey, RM | 1 |
| Brown, D; Chow, A; Eliasof, S; Foster, FS; Jayaraman, L; Kerbel, RS; Lazarus, D; Lee, CR; Man, S; Peters, CG; Pham, E; Rohde, E; Xu, P; Yin, M | 1 |
| Arrojo, R; Cardillo, TM; Goldenberg, DM; Mostafa, AA; Rossi, DL; Sharkey, RM | 1 |
| Abramson, V; Bardia, A; Berlin, J; Diamond, JR; Goldenberg, DM; Govindan, SV; Guarino, M; Isakoff, SJ; Juric, D; Kalinsky, K; Maliakal, P; Mayer, IA; Messersmith, WA; Moroose, RL; O'Shaughnessy, J; Ocean, AJ; Shah, NC; Sharkey, RM; Starodub, AN; Tolaney, SM; Vahdat, LT; Wegener, WA | 1 |
20 review(s) available for camptothecin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Antibody drug conjugates for patients with breast cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Receptor, ErbB-3; Triple Negative Breast Neoplasms | 2021 |
Role of sacituzumab govitecan in solid tumors.
Topics: Adult; Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Quality of Life; Triple Negative Breast Neoplasms | 2022 |
The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2022 |
Sacituzumab Govitecan-hziy in Breast Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2022 |
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Hormones; Humans; Immunoconjugates; Irinotecan; Triple Negative Breast Neoplasms | 2022 |
Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
Topics: Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2023 |
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
Topics: Antigens, Neoplasm; Camptothecin; Diarrhea; Humans; Immunoconjugates; Prospective Studies; Triple Negative Breast Neoplasms | 2023 |
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Female; Humans; Immunoconjugates; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2019 |
Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Female; Humans; Immunoconjugates; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2019 |
Sacituzumab Govitecan: First Approval.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Approval; Female; Humans; Immunoconjugates; Molecular Structure; Triple Negative Breast Neoplasms | 2020 |
Bispecific Antibodies for Triple Negative Breast Cancer.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Clinical Trials as Topic; Female; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Medical Oncology; Molecular Targeted Therapy; Survival Rate; T-Lymphocytes, Cytotoxic; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Humans; Immunoconjugates; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2021 |
Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Trastuzumab; Triple Negative Breast Neoplasms | 2021 |
[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; DNA Repair-Deficiency Disorders; Female; Genes, BRCA1; Genes, BRCA2; Humans; Immunoconjugates; Immunotherapy; Immunotherapy, Adoptive; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Female; Glucuronosyltransferase; Humans; Immunoconjugates; Survival Analysis; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms | 2021 |
Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cyclin-Dependent Kinase Inhibitor Proteins; Drug Therapy, Combination; Female; Furans; High-Intensity Focused Ultrasound Ablation; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy; Ketones; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Purinergic P1 Receptor Antagonists; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Immunoconjugates; Quality of Life; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Trastuzumab; Triple Negative Breast Neoplasms | 2021 |
Antibody-drug conjugates in triple negative breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Membrane Glycoproteins; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2018 |
Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Female; Humans; Immunoconjugates; Prognosis; Triple Negative Breast Neoplasms | 2019 |
7 trial(s) available for camptothecin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2022 |
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Camptothecin; Drug and Narcotic Control; Drug Approval; Female; Humans; Immunoconjugates; Middle Aged; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Drug Resistance, Neoplasm; Female; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Survival Analysis; Triple Negative Breast Neoplasms; Tumor Burden | 2021 |
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2021 |
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Progression-Free Survival; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2014 |
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms, Male; Camptothecin; Cell Adhesion Molecules; Female; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2017 |
33 other study(ies) available for camptothecin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds; Humans; Polycyclic Compounds; Quinazolines; Triple Negative Breast Neoplasms | 2021 |
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Language; Triple Negative Breast Neoplasms | 2021 |
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2021 |
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
Topics: Adult; Antibodies, Monoclonal, Humanized; Camptothecin; Female; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Immunoconjugates; Neutropenia; Triple Negative Breast Neoplasms; Uridine Diphosphate | 2022 |
New data for sacituzumab govitecan-hziy in the treatment of metastatic triple-negative breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2021 |
[Ⅳ. Development of Antibody-Drug Conjugate in Triple Negative Breast Cancer].
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Cell Line, Tumor; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2021 |
[New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Drug Approval; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2022 |
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Humans; Immunoconjugates; Mutation; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Triple Negative Breast Neoplasms | 2022 |
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Topics: Antigens, Neoplasm; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Irinotecan; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Tamoxifen; Transcription Factors; Triple Negative Breast Neoplasms | 2022 |
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Surface; Camptothecin; Female; Humans; Immunoconjugates; Triple Negative Breast Neoplasms; Trophoblasts | 2022 |
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Consensus; Cytotoxins; Female; Humans; Immunoconjugates; Neutropenia; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms; Ventricular Function, Left | 2022 |
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
Topics: Camptothecin; East Asian People; Female; Humans; Immunoconjugates; Middle Aged; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2023 |
Camptothecin loaded casein nanosystem for tuning the therapeutic efficacy against highly metastatic triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Caseins; Cell Line, Tumor; Humans; Nanoparticles; Triple Negative Breast Neoplasms; Zebrafish | 2023 |
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Topics: Aged; Camptothecin; Cost-Benefit Analysis; Humans; Medicare; Triple Negative Breast Neoplasms; United States | 2023 |
Tumor targeted combination therapeutic system for the effective treatment of drug resistant triple negative breast cancer.
Topics: Camptothecin; Cell Line, Tumor; Dopamine; Drug Carriers; Humans; Nanoparticles; Triple Negative Breast Neoplasms | 2023 |
Sacituzumab govitecan improves OS in heavily pretreated patients.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2023 |
A closer look at sacituzumab govitecan-hziy.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Female; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2020 |
Sacituzumab govitecan activity in advanced breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Clinical Trials, Phase II as Topic; Female; Humans; Immunoconjugates; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
[A Case of Triple Negative Spindle Cell Carcinoma of the Breast and Improved Quality of Life Following Irinotecan Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Camptothecin; Carcinoma; Female; Humans; Irinotecan; Middle Aged; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Brain Neoplasms; Camptothecin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Oxonic Acid; Pyridines; Tegafur; Triple Negative Breast Neoplasms | 2018 |
Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Floxuridine; Humans; Lovastatin; Mice; Nanocapsules; Triple Negative Breast Neoplasms | 2018 |
Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dimerization; Dithiothreitol; Drug Carriers; Endocytosis; Female; Fluorescence Resonance Energy Transfer; HEK293 Cells; Humans; Ligands; Mice; Micelles; Nanoparticles; Neoplasms; Neurotensin; Oxidation-Reduction; Polymers; Prodrugs; Temperature; Triple Negative Breast Neoplasms | 2018 |
Sacituzumab govitecan-hziy for triple-negative breast cancer.
Topics: Administration, Intravenous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
ADC Could Benefit Some with Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2019 |
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2019 |
Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Humans; Immunoconjugates; Triple Negative Breast Neoplasms | 2019 |
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Diseases; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cohort Studies; Exosomes; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2014 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Drug Synergism; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
An ADC for Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Female; Humans; Immunoconjugates; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Camptothecin; Cell Line, Tumor; Cyclodextrins; Female; Humans; Mice; Mice, SCID; Nanoparticles; Triple Negative Breast Neoplasms | 2016 |
Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Camptothecin; Cell Line, Tumor; DNA Repair; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Indoles; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |